AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03794076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cromoglycate
Description: Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
Study NCT03794076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
Study NCT03794076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
Study NCT01451970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Fat Diet
Description: Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
Study NCT02663102 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
Study NCT00656851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30mg/day for 16 weeks
Study NCT00656851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
Study NCT04334343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Muscle Biopsy Collection
Description: Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
Study NCT02117921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one interview and educational sessions. Reading material for educational series provided.
Description: A one-on-one interview with the patient and the principal investigator and group educational sessions.
Study NCT02604498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Single dose 500mg oral
Study NCT02726906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-aerobic walking
Study NCT02726906 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography (PET) scan
Description: Radioligand that binds to proteins using a PET/CT scanner.
Study NCT02726906 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: Radioligand that binds to proteins using a PET/CT scanner.
Study NCT02726906 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy living education
Study NCT02726906 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity monitor
Description: Wrist device that will track daily physical activity
Study NCT02726906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity monitor
Description: Wrist device that will track daily physical activity
Study NCT03660189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two bag system
Description: The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
Study NCT03448575 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control - Provider Medication Alert Only
Description: Simple text medication alert referencing Choosing Wisely guidelines.
Study NCT03448575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention - Alert + CAP Review AND Enhanced BH Access
Description: Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Study NCT03051256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
Study NCT03051256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
Study NCT05178355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active
Study NCT03798301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-specific T-cells
Description: Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (U300)
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meglitinides
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiazolidinediones
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-glucosidase inhibitors
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP1 Receptor Agonist
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-IV (DPP-IV) inhibitors
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02954692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium-glucose transport-2 (SGLT-2) inhibitors
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT05437874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later
Study NCT05437874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later
Study NCT05437874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later
Study NCT00922506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin plus tolterodine SR
Description: doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
Study NCT01399047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
Study NCT01399047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liquid Placebo
Description: The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
Study NCT02364323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Risk Counselling
Description: Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
Study NCT02364323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal usual care
Description: General education on diabetes and diabetic complications
Study NCT02729363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Relaxation video clip
Description: This intervention is a 12-minute guided audio-visual relaxation intervention.
Study NCT02729363 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sickle Cell Disease Experience Discussion
Description: This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
Study NCT01986127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: single intralesional administration during endoscopy process
Study NCT01986127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single intralesional administration during endoscopy
Study NCT05509465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergonomic chinrest
Description: The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
Study NCT05509465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergonomic chinrest used with a low Super Kun shoulder rest
Description: The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
Study NCT03196661 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza A (H7N9) virus vaccine
Description: To prevent the infection of H7N9 virus.
Study NCT02492555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SI
Description: A routine scheduled (SI) screening of FC and DA every 3rd month
Study NCT02492555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OD
Description: A screening of FC and DA on demand (OD)
Study NCT04598854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood
Description: Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
Study NCT04598854 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravascular laser irradiation of blood (Sham)
Description: zero intensity of the laser energy
Study NCT02421666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNMI
Description: Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
Study NCT00255346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 70 mg orally twice daily
Study NCT02378558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagneMarker
Description: The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
Study NCT04269018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer specific Mobile text message
Description: The intervention is cancer specific lifestyle mobile text messages daily for 2 months
Study NCT04269018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health messages
Description: Daily text related with general health message
Study NCT02093663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine/Mesalazine (Low Dose)
Description: Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing > 35 kg to \<= 50 kg; 2400 mg/day for participants weighing > 50 kg to \<= 90 kg.
Study NCT02093663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine/Mesalazine (High Dose)
Description: Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing > 23 kg to \<= 35 kg; 3600 mg/day for participants weighing > 35 kg to \<= 50 kg; 4800 mg/day for participants weighing > 50 kg to \<= 90 kg.
Study NCT01373216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
Study NCT03793465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry concentrate
Description: Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
Study NCT02636569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical diclofenac daily
Description: Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed.
Study NCT02636569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun.
Study NCT04715399 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00864708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radio frequency-controlled (RF) Microstimulator (RFM) Gait System
Description: Fully Implanted FES system to assist patient with gait component practice
Study NCT03010462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexstim NBS guided active rTMS
Description: Nexstim NBS guided active rTMS + standardized task-oriented therapy
Study NCT03010462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nexstim NBS guided sham rTMS
Description: Nexstim NBS guided sham rTMS + standardized task-oriented therapy
Study NCT05178355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo
Study NCT01198288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: domiciliary rehabilitation
Description: a respiratory rehabilitation programme at the patient home
Study NCT02206464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA071-00-VP
Description: H7 DNA Vaccine
Study NCT01198288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: As describe in the standard care arm
Study NCT01826890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA Technology
Description: Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
Study NCT02643797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Assistant Health Coaching
Description: One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
Study NCT03417089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Falciform ligament suspension
Description: routine of falciform ligament suspension during Mini gastric bypass
Study NCT03417089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no suspension
Description: working without of falciform ligament suspension during Mini gastric bypass
Study NCT04529785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVC only
Description: Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
Study NCT04529785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVC isolation with substrate modification and vein of Marshal ethanol infusion
Description: Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
Study NCT03694964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProteoCIT®
Description: 30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
Study NCT03694964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
Study NCT02799472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study NCT02799472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
Study NCT04353544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed cord clamping
Description: delayed cord clamping
Study NCT02799472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Capsule, tablet or liquid administered orally or as SC injection.
Study NCT04353544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: delayed cord clamping